|
Match
|
Document |
Document Title |
|
|
8183352 |
Attenuated vif DNA immunization cassettes for genetic vaccines
The present invention is directed to nucleic acid molecules encoding attenuated, non-functional virion infectivity factor (vif) proteins. The nucleic acid molecules of the invention are inserted...
|
|
|
8183220 |
Double-effective vaccine vector against foot-and-mouth disease virus (FMDV), methods of preparing and using the same
A double-effective vaccine vector against foot-and-mouth disease virus having a bicistronic expression vector sequence, the bicistronic expression vector sequence is an antisense gene sequence...
|
|
|
8183433 |
Method of controlling gene expression in plants or plant cells
A method of controlling a genetically-modified plant or plant cells, said method comprising the following steps: (a) providing a genetically-modified plant or plant cells, said plant or plant cells...
|
|
|
8183358 |
Puumala virus full-length M segment-based DNA vaccines
The invention contemplates a new synthetic, codon-optimized Puumala virus (PUUV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The PUUV ORF was...
|
|
|
8173137 |
Polycistronic HIV vector constructs
The present disclosure relates to vectors comprising polynucleotide sequences that encode HIV polypeptides. In particular, the disclosure relates polycistronic vector constructs comprising...
|
|
|
8168772 |
Nucleic acids encoding novel chimeric C15/prM/E dengue virus immunogens prepared by DNA shuffling
The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and...
|
|
|
8168200 |
Vaccine against african horse sickness virus
The present invention provides vectors that contain and express in vivo the genes encoding VP2 and VP5 of African Horse Sickness Virus or an epitope thereof that elicits an immune response in a...
|
|
|
8168771 |
Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
The invention provides consensus sequences for hepatitis C virus 1a and 1b. Also provided are non-synonymous changes for each residue of the consensus sequences. These sequences are useful as...
|
|
|
8163530 |
Nucleic acids encoding respiratory syncytial virus subgroup B strain 9320
The complete polynucleotide sequence of the human respiratory syncytial virus subgroup B strain 9320 genome is provided. Proteins encoded by this polynucleotide sequence are also provided. Isolated...
|
|
|
8163893 |
Pseudotyped retroviral vectors and methods of use thereof
The present invention provides nucleic acids encoding recombinant envelope proteins; and packaging cells comprising the nucleic acids, which packaging cells provide for encapsidation of recombinant...
|
|
|
8158855 |
Immunization of fish with plant-expressed recombinant proteins
Plants are produced that express an amino acid sequence that, when administered to a fish, produce an antigenic or immune response in the fish. The amino acid sequence in one embodiment is an...
|
|
|
8153115 |
Virus-like particles for treatment of viral infections
The invention provides virus-like particles for treatment of viral infections based on the virus causing the infection. The virus-like particles comprise the virus recombinant proteins that form a...
|
|
|
8148509 |
Transgene delivering retrovirus targeting collagen exposed at site of tissue injury
A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds...
|
|
|
8138390 |
Biological control agent for plants
A biological control agent for plants and a method of inoculating the plants with the biological control agent in order protect against plant disease are provided. The treatment method consists of...
|
|
|
8133494 |
Expression cassettes endcoding HIV-1 south african subtype C modified ENV proteins with deletions in V1 and V2
The invention relates to polynucleotides encoding modified immunogenic HIV-1 South African subtype C Env polypeptides. The modifications to the Env polypeptides include deletions of V1, V2 and the...
|
|
|
8128938 |
Influenza virus vaccine composition and methods of use
The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one...
|
|
|
8128937 |
N protein mutants of porcine reproductive and respiratory syndrome virus
The present invention provides a genetically modified PRRS virus, methods to make it and related polypeptides, polynucleotides and various components. Vaccines comprising the genetically modified...
|
|
|
8124747 |
HCV clade and prototype sequences thereof
The current invention relates to a previously unrecognized clade of HCV genotypes as well as to diagnostic, prophylactic and therapeutic applications of nucleic acids, proteins, and antibodies to...
|
|
|
8124103 |
Influenza antigens, vaccine compositions, and related methods
The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by influenza...
|
|
|
8114977 |
Proteins derived from white spot syndrome virus and uses thereof
Embodiments of the present invention generally relate to proteins derived from white spot syndrome virus, nucleic acid sequences encoding them, and their use in the manufacture of a vaccine for...
|
|
|
8114416 |
Modified oncolytic viruses
An isolated selected Picornavirus capable of lytically infecting or killing a cell substantially in the absence of intercellular adhesion molecule-1 (ICAM-1).
|
|
|
8110390 |
PRRS viruses, infectious clones, mutants thereof, and methods of use
The present invention provides isolated infectious polynucleotides, such as infectious clones, having a nucleotide sequence with identity to PRRS viruses such as VR-2332, Lelystad, or others, and...
|
|
|
8101739 |
Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector
The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively...
|
|
|
8093054 |
Metabolically activated recombinant viral vectors and methods for their preparation and use
Recombinant viral vectors, especially parvovirus vectors such as adeno-associated virus (AAV) vectors; capable of enhanced expression of heterologous sequences, and methods for their construction...
|
|
|
8088910 |
Isolated multiple sclerosis (MS)-associated retrovirus (MSRV) nucleic acids corresponding to the gag region
An isolated polynucleotide having a nucleotide sequence selected from the group consisting of (a) SEQ ID NO: 21, (b) the full-length sequences encoding a polypeptide having a peptide sequence...
|
|
|
8088902 |
DNA virus microRNA and methods for inhibiting same
The invention relates to isolated nucleic acid molecules comprising the sequence of a human cytomegalovirus microRNA. In another embodiment, the invention relates to single stranded DNA virus...
|
|
|
8080525 |
Peptide compositions and their use against the hepatitis C virus
Novel peptide compositions are described. In particular, peptide compositions are described which include at least two peptides which are selected from among the following peptides: a peptide A...
|
|
|
8071364 |
Gene therapy using transposon-based vectors
Methods and compositions are presented for the administration of transposon based vectors to an animal or human to provide gene therapy to the animal or human.
|
|
|
8071107 |
Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins
The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an...
|
|
|
8067566 |
Dengue serotype 2 attenuated strain
The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells...
|
|
|
8067010 |
Immunological herpes simplex virus antigens and methods for use thereof
The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by...
|
|
|
8067565 |
Dengue serotype 1 attenuated strain
The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on...
|
|
|
8063195 |
Mutations in a toll-like receptor motif in the NS4B of classical swine fever virus strain brescia influences virulence in swine
NS4B is one of the non-structural proteins of classical swine fever virus. By using functional genetics, we have discovered, in the predicted amino acid sequence of NS4B of CSFV strain Brescia, a...
|
|
|
8052967 |
Stable adenoviral vectors and methods for propagation thereof
Provided are methods and means to increase the stability and/or the packaging capacity of recombinant adenoviruses, by overexpression of pIX in an adenoviral packaging cell, by retaining at least a...
|
|
|
8052966 |
Methods and compositions for treating metastatic cancer
Methods and compositions for producing targeted delivery vectors are provided. Such vectors are useful for treating neoplastic disorders. Also provided are protocols for administering targeted...
|
|
|
8052974 |
Host cell specific binding molecules capable of neutralizing viruses and uses thereof
The present invention provides human binding molecules specifically binding to a host cell protein and having virus neutralizing activity, nucleic acid molecules encoding the human binding...
|
|
|
8053632 |
Method of controlling cellular processes in plants
A method of controlling a genetically-modified plant, comprising (a) providing a genetically-modified plant, whereby cells of said genetically-modified plant contain a heterologous nucleic acid and...
|
|
|
8053568 |
Bacterial packaging strains useful for generation and production of recombinant double-stranded RNA nucleocapsids and uses thereof
Bacterial packaging strains useful for generating recombinant double-stranded RNA nucleocapsids (rdsRNs) are provided. The packaging strains are useful for the production of RNA encoding vaccine...
|
|
|
8053553 |
Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
Disclosed are compositions and methods for preventing or reducing harm resulting from pathogen infection. For example, disclosed are peptides that inhibit the processing of toxins normally cleaved...
|
|
|
8039606 |
Seneca Valley virus based compositions and methods for treating disease
The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic aci...
|
|
|
8039688 |
Geminivirus resistant transgenic plants
Transgenic plants with increased resistance to geminivirus infection, and nucleic acid constructs useful in producing such plants, are described. In addition, methods of making the transgenic...
|
|
|
8034335 |
High-titer retroviral packaging cells
The present invention relates to non-replicative recombinant retrovirus packaging cells able to grow in suspension in a serum-free medium. In particular, the present invention relates to a human...
|
|
|
8034620 |
Lentiviral packaging cells and uses therefor
Novel packaging cell lines which produce recombinant retrovirus, free of detectable helper-virus are disclosed. Also disclosed are methods of making the cell lines and methods of producing...
|
|
|
8030029 |
Flu vaccines and methods of use thereof
This disclosure is directed, inter alia, to polynucleotides, polypeptides, vectors, cells and compositions comprising the same, and their use in affecting viral pathogenesis, in particular for...
|
|
|
8029776 |
Cationic lipid-mediated enhancement of nucleic acid immunization of cats
The present invention relates to a method to introduce a nucleic acid molecule into a felid by administration of a nucleic acid-cationic lipid complex composition. The method includes the step of...
|
|
|
8022175 |
Production of anti-peptide monoclonal antibodies to distinguish Exotic New Castle diseases viruses from vaccine strains of Newcastle disease virus
Anti-peptide monoclonal antibodies (MAb's) specific for Exotic Newcastle Disease (END) are used for rapid diagnostic identification between poultry infected with vaccine strains of NDV (LaSota/B1)...
|
|
|
8022197 |
Nucleic acid and gene derived from novel HCV strain and replicon-replicating cell using said gene
The present invention relates to a gene derived from a novel fulminant hepatitis C virus strain, an HCV replicon RNA with a high replication efficiency obtained using the gene, and an HCV...
|
|
|
8017754 |
Attenuated virus strains and uses thereof
Methods and compositions concerning mutant flaviviruses with reduced virulence. In some embodiments the invention concerns nucleotide sequences that encode mutant flaviviral proteins. Viruses...
|
|
|
8017126 |
Modified HIV-1 envelope proteins
The present invention relates to modified HIV-1 envelope proteins which express epitopes that produce a broadly cross reactive neutralizing response, their methods of use and antibodies which bind...
|
|
|
8008268 |
Vaccines against vesicular stomatitis
The present invention relates to an immunogenic or vaccine composition to induce an immune response or protective immune response against vesicular stomatitis virus (VSV) in an animal susceptible...
|